QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
NCT ID: NCT06716970
Last Updated: 2024-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
810 participants
INTERVENTIONAL
2024-12-30
2027-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
QR12000 75mg
Participants will be treated with one tablet of QR12000 75mg, one tablet of QR12000 150mg placebo and one tablet of Sacubitril/valsartan 200 mg placebo once daily for up to 8 weeks. Participants continue with one tablet of QR12000 150mg once daily for 44 weeks during TOP observation period.
QR12000 75mg
QR12000 75mg QD
QR12000 150mg placebo
Matching placebo of QR12000 150mg QD
Sacubitril/valsartan 200mg placebo
Matching placebo of Sacubitril/valsartan 200mg QD
QR12000 150mg
Participants will be treated with one tablet of QR12000 150mg, one tablet of QR12000 75mg placebo and one tablet of Sacubitril/valsartan 200 mg placebo once daily for up to 8 weeks. Participants continue with one tablet of QR12000 150mg once daily for 44 weeks during TOP observation period.
QR12000 75mg placebo
Matching placebo of QR12000 75mg QD
QR12000 150mg
QR12000 150mg QD
Sacubitril/valsartan 200mg placebo
Matching placebo of Sacubitril/valsartan 200mg QD
Sacubitril/valsartan 200 mg
Participants will be treated with one tablet of Sacubitril/valsartan 200 mg, one tablet of QR12000 75mg placebo and one tablet of QR12000 150mg placebo once daily for up to 8 weeks. Participants continue with one tablet of QR12000 150mg once daily for 44 weeks during TOP observation period.
QR12000 75mg placebo
Matching placebo of QR12000 75mg QD
QR12000 150mg placebo
Matching placebo of QR12000 150mg QD
Sacubitril/valsartan 200mg
Sacubitril/valsartan 200mg QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QR12000 75mg
QR12000 75mg QD
QR12000 75mg placebo
Matching placebo of QR12000 75mg QD
QR12000 150mg
QR12000 150mg QD
QR12000 150mg placebo
Matching placebo of QR12000 150mg QD
Sacubitril/valsartan 200mg
Sacubitril/valsartan 200mg QD
Sacubitril/valsartan 200mg placebo
Matching placebo of Sacubitril/valsartan 200mg QD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Man or woman aged 18 years to 75 years (inclusive), with BMI≤30 kg/m2.
3. Patients with moderate to severe hypertension. Untreated patients must have an msSBP ≥ 160 mmHg and \< 190 mmHg at the screening and randomization visit; Treated patients must have an msSBP≥150 mmHg and \<180 mmHg or msSBP≥140 mmHg and \<170 mmHg at the screening visit based on numbers of antihypertensive and msSBP≥160 mmHg \<190 mmHg at the randomization visit; Patients must have an absolute difference of ≤20 mmHg in msSBP between randomization visit and the immediately preceding visit.
4. Subjects who agree to use adequate contraception from 2 weeks prior to screening to 1 month after last dose.
Exclusion Criteria
2. History of peripheral arterial occlusive disease and Raynaud's syndrome.
3. History of hyperthyroidism.
4. History of hypotension.
5. History of angioedema, drug-related or otherwise.
6. Suffered by severe cerebrovascular disease within 1 year prior to screening.
7. Suffered by severe heart disease within 1 year prior to screening
8. History of severe or malignant retinopathy.
9. History of aortic aneurysm or dissection, cardiac surgery, or percutaneous coronary intervention within 1 year prior to screening.
10. History of malignant tumor within 5 years prior to screening.
11. Poorly controlled diabetes prior to screening
12. History of severe autoimmune diseases.
13. History of severe mental disorder.
14. Clinically significant laboratory abnormalities.
15. History of allergy to the test drug, active control drug, or drugs similar to the test drug and positive control drug or related excipients.
16. Undergone gastrointestinal surgery that could significantly alter drug absorption, distribution, metabolism, and excretion, or with severe gastrointestinal diseases, dysphagia, or recurrent vomiting that causes difficulty in eating or taking medication.
17. Intolerance to the run-in period.
18. Poor medication compliance or other non-compliance during run-in period.
19. Participated in any interventional clinical trial within 3 months prior to screening, plan to participate in another clinical trial during the period of this trial, or plan to participate in another clinical trial within 1 month after the end of this trial.
20. History of alcohol abuse within 6 months prior to screening or evidence of drug abuse.
21. Not agree or unable to comply with the restrictions on concomitant treatment during the study.
22. Pregnancy test positive, lactating women, or women planning to become pregnant.
23. High-altitude workers or large motor vehicle drivers and other professionals engaged in hazardous mechanical operations.
24. Other conditions that by the investigator's discretion may interfere with efficacy or safety assessment of the study, or pose a great risk to the subject.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuhan Createrna Science and Technology Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Wuhan Createrna Science and Technology Co.,Ltd
Role: CONTACT
Phone: +86 027-68788900
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jianping Li
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QR12000-GXY-3-01
Identifier Type: -
Identifier Source: org_study_id